๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

โœ Scribed by B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; J.A. Williams; S. Kim; R.J. Motzer


Book ID
119624018
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
70 KB
Volume
11
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES